Jonathan Biller - 09 Feb 2024 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
09 Feb 2024
Net transactions value
-$1,399,133
Form type
4
Filing time
13 Feb 2024, 16:56:51 UTC
Previous filing
08 Feb 2024
Next filing
03 Oct 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Tax liability $671,311 -1,588 -7.3% $422.74 20,018 09 Feb 2024 Direct
transaction VRTX Common Stock Sale $727,822 -1,738 -8.7% $418.77 18,280 12 Feb 2024 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023.
F2 Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $418.77 (range $418.76 to $418.82).